Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 18, Number 1—January 2012

Molecular Evolution of Respiratory Syncytial Virus Fusion Gene, Canada, 2006–2010

Jesse Papenburg, Julie Carbonneau, Marie-Ève Hamelin, Sandra Isabel, Xavier Bouhy, Najwa Ohoumanne, Pierre Déry, Bosco A. Paes, Jacques Corbeil, Michel G. Bergeron, Gaston De Serres, and Guy BoivinComments to Author 
Author affiliations: McGill University Health Centre, Montréal, Québec, Canada (J. Papenburg); Centre de Recherche du Centre Hospitalier Universitaire de Québec, Québec City, Québec, Canada (J. Papenburg, J. Carbonneau, M.-È. Hamelin, S. Isabel, X. Bouhy, P. Déry, J. Corbeil, M.G. Bergeron, G. Boivin); Institut National de Santé Publique du Québec, Québec (N. Ohoumanne, G. De Serres); McMaster Children’s Hospital, Hamilton, Ontario, Canada (B.A. Paes)

Main Article


Figure. Phylogenetic analysis of 170 near–full-length unique respiratory syncitial virus fusion (RSV-F) gene sequences (nt 79–1602). Panels A and B are detailed phylograms of the RSV-A and RSV-B taxa analyzed, respectively. One bovine RSV-F sequence was added to the dataset (GenBank accession no. AF295543.1) as the outgroup (not shown) and used for rooting the phylograms. Topology was inferred by using the neighbor-joining method, and evolutionary distances were computed by using the maximum-composite likelihood method in MEGA5 software ( The topologic accuracy of the tree was evaluated by using 1,000 bootstrap replicates. Only bootstrap values >50% are shown. Blue text and triangles represent RSV strains isolated in Canada and sequenced at the Centre de Recherche du Centre Hospitalier Universitaire de Québec; red branches indicates a sublineage of RSV-A with a N276S mutation; underlining indicates prototypical RSV A2 and RSV B1 strains. The clinical origin of strains from Canada (prospective study hospitalized patient [H] or clinic patient [C]; 2004–2005 palivizumab study patient [S]; retrospectively identified patient from the Montréal Children’s Hospital [MCH] or McMaster Children’s Hospital [MAC]) is indicated, followed by the year collected, the specimen identifier, and the result of RSV genogroup testing (RSV-A [A], RSV-B [B]) by multiplex PCR/DNA hybridization assay (14). Specimens with a nonsilent mutation at codon 272 have the amino acid substitution identified in brackets. When a taxon represents >1 identical sequences, the number of patients that it represents and the number of palivizumab recipients (PZB) among these patients are noted in parentheses. SA, South Africa; CHN, People’s Republic of China; UK, United Kingdom, JPN, Japan; AUS, Australia; USA, United States; CDC, US Centers for Disease Control and Prevention; NY, New York; SL, St. Louis; WV, West Virginia; MN, Minnesota; MD, Maryland; WA, Washington; SEL, Seoul, South Korea. Scale bars represent substitutions per basepair per the indicated horizontal distance.

Main Article

  1. Nair  H, Nokes  DJ, Gessner  BD, Dherani  M, Madhi  SA, Singleton  RJ, Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375:154555. DOIPubMedGoogle Scholar
  2. Welliver  RC. Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection. J Pediatr. 2003;143:S1127. DOIPubMedGoogle Scholar
  3. Collins  PL, Crowe  JE. Respiratory syncytial virus and metapneumovirus. In: Knipe DM, Howley PM, editors. Field’s virology.,5th ed. New York: Lippincott Williams and Wilkins; 2007. p. 1601–46.
  4. Crowe  JE, Firestone  CY, Crim  R, Beeler  JA, Coelingh  KL, Barbas  CF, Monoclonal antibody-resistant mutants selected with a respiratory syncytial virus–neutralizing human antibody fab fragment (Fab 19) define a unique epitope on the fusion (F) glycoprotein. Virology. 1998;252:3735. DOIPubMedGoogle Scholar
  5. Huang  K, Incognito  L, Cheng  X, Ulbrandt  ND, Wu  H. Respiratory syncytial virus–neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion. J Virol. 2010;84:813240. DOIPubMedGoogle Scholar
  6. Committee on Infectious Diseases. From the American Academy of Pediatrics: policy statements–modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics. 2009;124:1694701. DOIPubMedGoogle Scholar
  7. Zhao  X, Chen  FP, Megaw  AG, Sullender  WM. Variable resistance to palivizumab in cotton rats by respiratory syncytial virus mutants. J Infect Dis. 2004;190:19416. DOIPubMedGoogle Scholar
  8. Adams  O, Bonzel  L, Kovacevic  A, Mayatepek  E, Hoehn  T, Vogel  M. Palivizumab-resistant human respiratory syncytial virus infection in infancy. Clin Infect Dis. 2010;51:1858. DOIPubMedGoogle Scholar
  9. Zhu  Q, McAuliffe  JM, Patel  NK, Palmer-Hill  FJ, Yang  CF, Liang  B, Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab. J Infect Dis. 2011;203:67482. DOIPubMedGoogle Scholar
  10. Kim  YK, Choi  EH, Lee  HJ. Genetic variability of the fusion protein and circulation patterns of genotypes of the respiratory syncytial virus. J Med Virol. 2007;79:8208. DOIPubMedGoogle Scholar
  11. Zheng  H, Storch  GA, Zang  C, Peret  TC, Park  CS, Anderson  LJ. Genetic variability in envelope-associated protein genes of closely related group A strains of respiratory syncytial virus. Virus Res. 1999;59:8999. DOIPubMedGoogle Scholar
  12. Gilca  R, De Serres  G, Tremblay  M, Vachon  ML, Leblanc  E, Bergeron  MG, Distribution and clinical impact of human respiratory syncytial virus genotypes in hospitalized children over 2 winter seasons. J Infect Dis. 2006;193:548. DOIPubMedGoogle Scholar
  13. Peret  TC, Hall  CB, Hammond  GW, Piedra  PA, Storch  GA, Sullender  WM, Circulation patterns of group A and B human respiratory syncytial virus genotypes in 5 communities in North America. J Infect Dis. 2000;181:18916. DOIPubMedGoogle Scholar
  14. Raymond  F, Carbonneau  J, Boucher  N, Robitaille  L, Boisvert  S, Wu  WK, Comparison of automated microarray detection with real-time PCR assays for detection of respiratory viruses in specimens obtained from children. J Clin Microbiol. 2009;47:74350. DOIPubMedGoogle Scholar
  15. Boivin  G, Caouette  G, Frenette  L, Carbonneau  J, Ouakki  M, De Serres  G. Human respiratory syncytial virus and other viral infections in infants receiving palivizumab. J Clin Virol. 2008;42:527. DOIPubMedGoogle Scholar

Main Article

Page created: December 20, 2011
Page updated: December 20, 2011
Page reviewed: December 20, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.